Dermatology has become the central battleground for biologic differentiation. With multiple approved agents competing across atopic dermatitis, plaque psoriasis, hidradenitis suppurativa, and beyond, and a pipeline that continues to expand, the gap between what physicians say they prescribe and what is actually driving their decisions has never been more commercially consequential.

Spherix has tracked dermatology continuously for more than a decade, working with leading and emerging biopharma companies and investment firms shaping innovation in the category. The Spherix dermatology community is 600+ practicing dermatologists across the full spectrum of clinical practice, one of the largest specialist panels in the category, continuously screened for active practice and patient volume. Spherix publishes 50+ studies annually across physician, patient, and payer perspectives.